Hot Cheapest Stocks To Buy For 2016

Hot Cheapest Stocks To Buy For 2016: Amedisys Inc(AMED)

Amedisys, Inc., a health care company, provides home health and hospice services primarily in the United States. It operates in two segments, Home Health and Hospice. The Home Health segment offers various services in the homes of individuals who may be recovering from an illness, injury, or surgical procedure. This segment?s services include skilled nursing, home health aides, physical and occupational therapy, speech therapy, and medical social services; and chronic care clinical programs for patients with chronic diseases, such as cardiovascular, respiratory, diabetes, behavioral health, rehabilitative, and medical surgical conditions. The Hospice segment provides care that is designed to offer comfort and support for those who are facing a terminal illness, such as heart disease, pulmonary disease, dementia, Alzheimer?s, HIV/AIDS, or cancer. As of December 31, 2011, the company owned and operated 440 Medicare-certified home health care centers, 87 Medicare-certified ho spice care centers, and 2 hospice inpatient units in 41 states within the United States, the District of Columbia, and Puerto Rico. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Advisors' Opinion:

• [By Monica Gerson]

  Amedisys (NASDAQ: AMED) shares jumped more than 29% on Friday after the company issued Q2 outlook. The company projected its Q2 earnings of $0.15 to $0.20 per share on revenue of $300 million to $305 million. Amedisys shares surged 5.33% to $18.39 in after-hours trading.

• [By Brendan Conway]

  That zipping sound you hear is home-health providerAmedisys‘ (AMED) 24% surge on news thatprivate-equity giant Kohlberg Kravis Roberts & Co.has a stake of more than 8% in the stock.

  CRT Capital analyst Sheryl Skolnick, a critic of company management, upgrades to “fair value” this morning and essentially tells clients to get out of KKR’s wa! y, since the firm could end up ushering in a new board and management:

  There are times when this analyst will ‘take on’ shareholders with differing views and there are times when she knows, from long experience, not to even think about it. This is one of the latter times ….

  We know that when activists get involved, strange and interesting things happen, even (especially?) with entrenched managements. For the record, we think it unlikely that this part of KKR will take AMED private: filing a 13-D that almost surely takes the stock up would be that act of amateurs, in our view, not the act of a savvy firm like KKR. Some may conclude from the language of the 13-D that KKR may not actually become active. We reviewed it and found it nearly identical to other activists’ initial statements: then things changed. Thus, a new Board and management does seem likely and is indeed the strategy we advocated in our 4/3/13 report and THAT is the root cause of our upgrade.

  But for the 13-D we would NOT have upgraded. Indeed, we were in the midst of preparing a strong reiteration of our view that AMED cannot be fixed by this CEO and his Board. We reiterate that view here and strongly suspect that any activist likely has or will reach that same conclusion.

• [By Monica Gerson]

  Amedisys (NASDAQ: AMED) is expected to post a Q4 loss at $0.01 per share on revenue of $295.02 million.

  Williams-Sonoma (NYSE: WSM) is projected to post its Q4 earnings at $1.36 per share on revenue of $1.43 billion.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-cheapest-stocks-to-buy-for-2016.html